Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896569743> ?p ?o ?g. }
- W2896569743 endingPage "481" @default.
- W2896569743 startingPage "473" @default.
- W2896569743 abstract "Background Androgens were shown to play a key role in the growth and progression of pancreatic cancer. We evaluated the safety and tolerability of the combination of enzalutamide, a novel androgen receptor (AR) antagonist with gemcitabine and nab-paclitaxel as a first-line treatment in advanced pancreatic cancer. Methods We used the standard 3 + 3 dose escalation design with cohort expansion to evaluate 2 dose levels of enzalutamide: 80 mg and 160 mg/day orally (phase 1a) in combination with gemcitabine and nab-paclitaxel in metastatic pancreatic cancer patients. In the expansion phase (phase 1b), AR+ was a pre-requisite criterion. We also evaluated the full pharmacokinetic (PK) profile for nab-paclitaxel and enzalutamide. Results We enrolled 24 patients, 12 patients in phase 1a and 12 patients in phase 1b. The median age was 68 (range, 32–84) years. No DLTs were observed. Grade 3/4 treatment related adverse events included neutropenia (44%), anemia (40%), leukopenia (24%), nausea and vomiting (20%), diarrhea (16%), infections (12%), thrombocytopenia (8%), thromboembolic event (8%), hypertension (8%), hypokalemia (8%), hyponatremia (8%), and ALT elevation (8%). Median overall survival and progression-free survival was 9.73 [95%CI:9.73–13.5] and 7.53 (95%CI:6.05–12.8) months, respectively. PK analysis suggests that the combination therapy does not impact the kinetics of either drug evaluated. Enzalutamide reached steady-state levels between day 22 and 29 and the mean half-life of nab-paclitaxel was 19.6 ± 4.7 h. Conclusions Enzalutamide 160 mg daily in combination with gemcitabine and nab-paclitaxel can be safely administered with no unexpected toxicities. We also noticed preliminary signals of efficacy with this combination." @default.
- W2896569743 created "2018-10-26" @default.
- W2896569743 creator A5001725329 @default.
- W2896569743 creator A5002142386 @default.
- W2896569743 creator A5009041563 @default.
- W2896569743 creator A5009314752 @default.
- W2896569743 creator A5027090396 @default.
- W2896569743 creator A5030296219 @default.
- W2896569743 creator A5039697358 @default.
- W2896569743 creator A5054848065 @default.
- W2896569743 creator A5056210769 @default.
- W2896569743 date "2018-10-09" @default.
- W2896569743 modified "2023-10-16" @default.
- W2896569743 title "Phase 1 trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer" @default.
- W2896569743 cites W1592992548 @default.
- W2896569743 cites W1931508686 @default.
- W2896569743 cites W1964747228 @default.
- W2896569743 cites W1987329654 @default.
- W2896569743 cites W1990883345 @default.
- W2896569743 cites W2001360688 @default.
- W2896569743 cites W2013098300 @default.
- W2896569743 cites W2015864437 @default.
- W2896569743 cites W2019607817 @default.
- W2896569743 cites W2039896904 @default.
- W2896569743 cites W2045390516 @default.
- W2896569743 cites W2054422997 @default.
- W2896569743 cites W2069232632 @default.
- W2896569743 cites W2119504728 @default.
- W2896569743 cites W2151253787 @default.
- W2896569743 cites W2165480504 @default.
- W2896569743 cites W2170202192 @default.
- W2896569743 cites W2401831084 @default.
- W2896569743 cites W2781525129 @default.
- W2896569743 doi "https://doi.org/10.1007/s10637-018-0676-8" @default.
- W2896569743 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7771270" @default.
- W2896569743 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30298303" @default.
- W2896569743 hasPublicationYear "2018" @default.
- W2896569743 type Work @default.
- W2896569743 sameAs 2896569743 @default.
- W2896569743 citedByCount "9" @default.
- W2896569743 countsByYear W28965697432020 @default.
- W2896569743 countsByYear W28965697432021 @default.
- W2896569743 countsByYear W28965697432022 @default.
- W2896569743 countsByYear W28965697432023 @default.
- W2896569743 crossrefType "journal-article" @default.
- W2896569743 hasAuthorship W2896569743A5001725329 @default.
- W2896569743 hasAuthorship W2896569743A5002142386 @default.
- W2896569743 hasAuthorship W2896569743A5009041563 @default.
- W2896569743 hasAuthorship W2896569743A5009314752 @default.
- W2896569743 hasAuthorship W2896569743A5027090396 @default.
- W2896569743 hasAuthorship W2896569743A5030296219 @default.
- W2896569743 hasAuthorship W2896569743A5039697358 @default.
- W2896569743 hasAuthorship W2896569743A5054848065 @default.
- W2896569743 hasAuthorship W2896569743A5056210769 @default.
- W2896569743 hasBestOaLocation W28965697432 @default.
- W2896569743 hasConcept C121608353 @default.
- W2896569743 hasConcept C126322002 @default.
- W2896569743 hasConcept C143998085 @default.
- W2896569743 hasConcept C197934379 @default.
- W2896569743 hasConcept C2776551883 @default.
- W2896569743 hasConcept C2776694085 @default.
- W2896569743 hasConcept C2777063308 @default.
- W2896569743 hasConcept C2778375690 @default.
- W2896569743 hasConcept C2780192828 @default.
- W2896569743 hasConcept C2780210213 @default.
- W2896569743 hasConcept C2780258809 @default.
- W2896569743 hasConcept C2780873365 @default.
- W2896569743 hasConcept C61367390 @default.
- W2896569743 hasConcept C71924100 @default.
- W2896569743 hasConcept C90924648 @default.
- W2896569743 hasConceptScore W2896569743C121608353 @default.
- W2896569743 hasConceptScore W2896569743C126322002 @default.
- W2896569743 hasConceptScore W2896569743C143998085 @default.
- W2896569743 hasConceptScore W2896569743C197934379 @default.
- W2896569743 hasConceptScore W2896569743C2776551883 @default.
- W2896569743 hasConceptScore W2896569743C2776694085 @default.
- W2896569743 hasConceptScore W2896569743C2777063308 @default.
- W2896569743 hasConceptScore W2896569743C2778375690 @default.
- W2896569743 hasConceptScore W2896569743C2780192828 @default.
- W2896569743 hasConceptScore W2896569743C2780210213 @default.
- W2896569743 hasConceptScore W2896569743C2780258809 @default.
- W2896569743 hasConceptScore W2896569743C2780873365 @default.
- W2896569743 hasConceptScore W2896569743C61367390 @default.
- W2896569743 hasConceptScore W2896569743C71924100 @default.
- W2896569743 hasConceptScore W2896569743C90924648 @default.
- W2896569743 hasIssue "3" @default.
- W2896569743 hasLocation W28965697431 @default.
- W2896569743 hasLocation W28965697432 @default.
- W2896569743 hasOpenAccess W2896569743 @default.
- W2896569743 hasPrimaryLocation W28965697431 @default.
- W2896569743 hasRelatedWork W1833952634 @default.
- W2896569743 hasRelatedWork W2071805383 @default.
- W2896569743 hasRelatedWork W2076684456 @default.
- W2896569743 hasRelatedWork W2122349489 @default.
- W2896569743 hasRelatedWork W2408292629 @default.
- W2896569743 hasRelatedWork W2896569743 @default.
- W2896569743 hasRelatedWork W2913277547 @default.
- W2896569743 hasRelatedWork W3030111582 @default.